Taurine

Taurine Common Name

Taurine

Top Benefits of Taurine

  • Supports brain function *
  • Supports cognitive function *
  • Supports mood *
  • Supports antioxidant defenses *
  • Supports cardiovascular function *

Description

Taurine is an organic amino sulfonic acid naturally produced in our body.

Key Mechanisms

Brain function

  • Supports synaptic long-term potentiation [1]
  • Modulates GABAergic neurotransmission [2–5]
  • Modulates glycinergic neurotransmission [6]
  • Upregulates BDNF production [5]

Cognitive function

  • Supports short-term memory [5]

 Mood

  • Supports mood [6–9]

 Antioxidant defenses

  • Downregulates reactive oxygen species (ROS) production [10]
  • Downregulates ROS by supporting mitochondrial protein synthesis [11,12]
  • Upregulates antioxidant defenses [13–16]
  • Protects tissues from oxidative damage [8,16–18]

Cardiovascular function

  • Protects vascular endothelial cells [8,19]
  • Protects cardiac muscle cells [17,18]
  • Supports the generation of new blood vessels (angiogenesis) [20]
  • Supports healthy blood flow [19]

Metabolism

  • Supports healthy insulin sensitivity and glucose metabolism [13,21,22]

 

REFERENCES

[1] N. del Olmo, L.M. Suárez, L.M. Orensanz, F. Suárez, J. Bustamante, J.M. Duarte, R. Martín del Río, J.M. Solís, Eur. J. Neurosci. 19 (2004) 1875–1886.

[2] K. Kuriyama, T. Hashimoto, in: S. Schaffer, J.B. Lombardini, R.J. Huxtable (Eds.), pp. 329–337.

[3] M.H. Bureau, R.W. Olsen, Eur. J. Pharmacol. 207 (1991) 9–16.

[4] P. Kontro, S.S. Oja, Neuropharmacology 29 (1990) 243–247.

[5] G. Caletti, F.B. Almeida, G. Agnes, M.S. Nin, H.M.T. Barros, R. Gomez, 283 (2015) 11–15.

[6] C.G. Zhang, S.-J. Kim, Ann. 51 (2007) 379–386.

[7] W. Iio, N. Matsukawa, T. Tsukahara, A. Toyoda, 43 (2012) 2037–2046.

[8] G. Caletti, D.B. Olguins, E.F. Pedrollo, H.M.T. Barros, R. Gomez, 43 (2012) 1525–1533.

[9] A. Toyoda, W. Iio, Adv. Exp. Med. Biol. 775 (2013) 29–43.

[10] Q.D. Wu, J.H. Wang, F. Fennessy, H.P. Redmond, D. Bouchier-Hayes, Am. J. Physiol. 277 (1999) C1229–38.

[11] C.J. Jong, J. Azuma, S. Schaffer, (2012) 2223–2232.

[12] S.W. Schaffer, J. Azuma, M. Mozaffari, Can. J. 87 (2009) 91–99.

[13] A.T.A. Nandhini, V. Thirunavukkarasu, M.K. Ravichandran, C.V. Anuradha, 46 (2005) 82–87.

[14] P.S. Devamanoharan, A.H. Ali, S.D. Varma, Free Radic. Res. 29 (1998) 189–195.

[15] G. Guz, E. Oz, N. Lortlar, N.N. Ulusu, N. Nurlu, B. Demirogullari, S. Omeroglu, S. Sert, C. Karasu, 32 (2007) 405–411.

[16] H. Tabassum, S. Parvez, H. Rehman, B. Dev Banerjee, D. Siemen, S. Raisuddin,  26 (2007) 509–518.

[17] J. Hanna, R. Chahine, G. Aftimos, M. Nader, A. Mounayar, F. Esseily, S. Chamat, 56 (2004) 189–194.

[18] R. Kingston, C.J. Kelly, P. Murray, 10 (2004) 2401–2410.

[19] M.A. Moloney, R.G. Casey, D.H. O’Donnell, P. Fitzgerald, C. Thompson, D.J. Bouchier-Hayes, Diab. 7 (2010) 300–310.

[20] Y.-Y. Baek, D.H. Cho, J. Choe, H. Lee, D. Jeoung, K.-S. Ha, M.-H. Won, Y.-G. Kwon, Y.-M. Kim, Eur. J. 674 (2012) 188–199.

[21] A.T.A. Nandhini, V. Thirunavukkarasu, C.V. Anuradha, 31 (2005) 337–344.

[22] A.T.A. Nandhini, C.V. Anuradha, 22 (2002) 27–38.